17.03.2010 • NewsPfizerPharmaTekmira Pharmaceuticals

Tekmira, Pfizer to Collaborate on RNAi Delivery System

Canada's Tekmira Pharmaceuticals said it would collaborate with Pfizer to evaluate the potential of using its technology to deliver Pfizer's gene "silencing" mechanism to treat a range of diseases. Tekmira's shares shot up 20% after it announced the deal -- its first formal research collaboration with Pfizer.

Tekmira's technology, known as sable nucleic acid-lipid particle (SNALP), uses lipid nanoparticles to deliver RNAi therapeutics, such as siRNAs, to the disease site.

"The collaboration combines Tekmira's expertise in the delivery of RNAi therapeutics with Pfizer's research excellence in nucleic acid therapeutics," Mark Murray, Tekmira's chief executive officer said in statement.

Pfizer will evaluate Tekmira's SNALP formulations in preclinical models. Financial terms of the collaboration were not disclosed.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.